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Abstract
BACKGROUND
Matrix metalloproteinases (MMPs), including MMP-9, are an integral part of the
immune response and are upregulated in response to a variety of stimuli. New
details continue to emerge concerning the mechanistic and regulatory pathways
that mediate MMP-9 secretion. There is significant evidence for regulation of
inflammation by dimethyl sulfoxide (DMSO) and 3',5'-cyclic adenosine
monophosphate (cAMP), thus investigation of how these two molecules may
regulate both MMP-9 and tumor necrosis factor α (TNFα) secretion by human
monocytes was of high interest. The hypothesis tested in this study was that
DMSO and cAMP regulate MMP-9 and TNFα secretion by distinct mechanisms.
AIM
To investigate the regulation of lipopolysaccharide (LPS)-stimulated MMP-9 and
tumor necrosis factor α secretion in THP-1 human monocytes by dimethyl
sulfoxide and cAMP.
METHODS
The paper describes a basic research study using THP-1 human monocyte cells.
All experiments were conducted at the University of Missouri-St. Louis in the
Department of Chemistry and Biochemistry. Human monocyte cells were grown,
cultured, and prepared for experiments in the University of Missouri-St. Louis
Cell Culture Facility as per accepted guidelines. Cells were treated with LPS for
selected exposure times and the conditioned medium was collected for analysis of
MMP-9 and TNFα production. Inhibitors including DMSO, cAMP regulators, and
anti-TNFα antibody were added to the cells prior to LPS treatment. MMP-9
secretion was analyzed by gel electrophoresis/western blot and quantitated by
ImageJ software. TNFα secretion was analyzed by enzyme-linked immuno
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sorbent assay. All data is presented as the average and standard error for at least 3
trials. Statistical analysis was done using a two-tailed paired Student t-test. P
values less than 0.05 were considered significant and designated as such in the
Figures. LPS and cAMP regulators were from Sigma-Aldrich, MMP-9 standard
and antibody and TNFα antibodies were from R&D Systems, and amyloid-β
peptide was from rPeptide.
RESULTS
In our investigation of MMP-9 secretion from THP-1 human monocytes, we made
the following findings. Inclusion of DMSO in the cell treatment inhibited LPSinduced MMP-9, but not TNFα, secretion. Inclusion of DMSO in the cell treatment
at different concentrations inhibited LPS-induced MMP-9 secretion in a dosedependent fashion. A cell-permeable cAMP analog, dibutyryl cAMP, inhibited
both LPS-induced MMP-9 and TNFα secretion. Pretreatment of the cells with the
adenylyl cyclase activator forskolin inhibited LPS-induced MMP-9 and TNFα
secretion. Pretreatment of the cells with the general cAMP phosphodiesterase
inhibitor IBMX reduced LPS-induced MMP-9 and TNFα in a dose-dependent
fashion. Pre-treatment of monocytes with an anti-TNFα antibody blocked LPSinduced MMP-9 and TNFα secretion. Amyloid-β peptide induced MMP-9
secretion, which occurred much later than TNFα secretion. The latter two findings
strongly suggested an upstream role for TNFα in mediating LPS-stimulate MMP-9
secretion.
CONCLUSION
The cumulative data indicated that MMP-9 secretion was a distinct process from
TNFα secretion and occurred downstream. First, DMSO inhibited MMP-9, but not
TNFα, suggesting that the MMP-9 secretion process was selectively altered.
Second, cAMP inhibited both MMP-9 and TNFα with a similar potency, but at
different monocyte cell exposure time points. The pattern of cAMP inhibition for
these two molecules suggested that MMP-9 secretion lies downstream of TNFα
and that TNFα may a key component of the pathway leading to MMP-9 secretion.
This temporal relationship fit a model whereby early TNFα secretion directly led
to later MMP-9 secretion. Lastly, antibody-blocking of TNFα diminished MMP-9
secretion, suggesting a direct link between TNFα secretion and MMP-9 secretion.
Key Words: Matrix metalloproteinase-9; Inflammation; Human monocytes; Tumor
necrosis factor alpha; Cyclic adenosine monophosphate; Dimethyl sulfoxide
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This article describes the stimulation of matrix metalloproteinase-9 (MMP-9)
and tumor necrosis factor α (TNFα) secretion from human monocyte cells by
lipopolysaccharide, and the inhibition of this process by dimethyl sulfoxide and
increased intracellular levels of 3',5'-cyclic adenosine monophosphate. The
experimental findings demonstrated that dimethyl sulfoxide concentration must be
carefully controlled in inflammatory studies, that MMP-9 secretion occurred
downstream from TNFα secretion and that the two processes were distinct, and that
TNFα is an integral component of the pathway leading to MMP-9 secretion.

Citation: Denner DR, Udan-Johns ML, Nichols MR. Inhibition of matrix metalloproteinase-9
secretion by dimethyl sulfoxide and cyclic adenosine monophosphate in human monocytes.
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INTRODUCTION
Matrix-metalloproteinases (MMPs) are zinc-dependent extracellular matrix-degrading
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enzymes that have a key role in a wide variety of physiological[1] and pathological[2,3]
processes. Physiological processes include embryonic development, morphogenesis,
angiogenesis, tissue repair, and immune responses while pathological processes
include arthritis, cancer, neurological disease, breakdown of the blood–brain barrier,
and cerebral hemorrhage. MMP subgroups are comprised of collagenases, gelatinases,
stromalysins, and membrane-type and their activity is controlled by gene expression,
zymogen activation, and endogenous tissue inhibitors[4,5]. MMP-1, MMP-8, MMP-13,
and MMP-18 are collagenases that cleave interstitial collagen type I, II, and III and
digest some extracellular matrix and non-extracellular matrix proteins. MMP-2
(gelatinase A) and MMP-9 (gelatinase B) are gelatinases that degrade both collagens
and gelatins[3].
MMPs have been described as a type of inflammatory cytokine since they are
significantly expressed, secreted, and activated upon stimulation of inflammatory cells
by various endogenous or exogenous factors[2]. MMP-9 is an important MMP in
myeloid/monocyte cells and substantial work has been done on understanding the
types of stimuli and mechanistic pathways that lead to MMP-9 secretion. Stimulation
of inflammatory cells with lipopolysaccharide (LPS), cytokines, amino acids, and
protein aggregates such as amyloid-β (Aβ) triggers signaling pathways that involve
nuclear factor κB, protein kinase Cα, extracellular signal-regulated kinase 1 and 2 and
mitogen-activated kinase p38, and lead to MMP-9 secretion[6-9]. MMP-9 secretion, and
inflammation in general, can be regulated in a number of ways and there have been
previous reports of regulation by both dimethyl sulfoxide (DMSO)[9-11] and the
intracellular signaling molecule 3',5'-cyclic adenosine monophosphate (cAMP)[7].
DMSO is commonly used as a vehicle for delivering hydrophobic compounds, such
as enzyme inhibitors or signaling regulators to cells, thus its role as an inflammatory
regulator is of significant interest. DMSO inhibited production of MMP-9 in TNFαstimulated human keratinocytes at concentrations of 0.75% and higher[9]. DMSO also
decreased interleukin-1β (IL-1β)-induced interleukin-6 and macrophage
chemoattractant protein-1 secretions in a dose-dependent manner in differentiatedCaco-2 cells[10]. Suppression of many pro-inflammatory cytokines/chemokines by
DMSO in Escherichia coli- and herpes simplex virus-1-stimulated whole human blood
has also been demonstrated[11]. Cyclic AMP is a critical signaling molecule and is
involved in a myriad of physiological cellular processes including regulation of
inflammatory processes. Support for this regulation includes the observation that
adenosine dose-dependently decreased MMP-9 secretion in isolated human
neutrophils regardless of whether the cells were stimulated by N-formylmethionylleucyl-phenylalanine, LPS, or H2O2[7]. Adenosine increased intracellular cAMP levels
and it was concluded that the effect was mediated through a cAMP-mediated
pathway[7].
MMP-9 and TNFα are important markers and mediators of inflammatory processes
in immune cells. In this report we sought to further examine temporal and regulatory
mechanisms of MMP-9 secretion in THP-1 human monocytes after stimulation with
LPS. Specifically, dose-dependent regulation of MMP-9 and TNFα by the aprotic
solvent DMSO and the intracellular signaling molecule cAMP. The findings
demonstrated distinct regulatory effects by DMSO and cAMP on MMP-9 and TNFα
secretion. These distinct, but significant and efficacious, effects by DMSO and cAMP
revealed a probable role for TNFα in the pathway leading to MMP-9 secretion.

MATERIALS AND METHODS
Cellular assays
THP-1 monocytic cells were obtained from ATCC (Manassas, VA, United States) and
maintained in RPMI-1640 culture medium (HyClone, Logan, UT, United States)
containing 2 mmol/L L-glutamine, 25 mmol/L HEPES, 1.5 g/L sodium bicarbonate,
10% fetal bovine serum (HyClone), 50 U/mL penicillin, 50 mg/mL streptomycin
(HyClone), and 50 mmol/L β-mercaptoethanol at 37 °C in 5% CO2. For cell assays,
THP-1 cells were centrifuged at 500 g for 10 min, washed, and resuspended in reduced
fetal calf serum (2%) growth medium. Cell concentrations were adjusted to 1.0 × 106
cells/mL and 0.3 mL (3.0 × 105 cells) was added to individual wells of a 48-well sterile
culture plate. For experiments evaluating the regulatory effect of DMSO on LPSstimulated MMP-9 and TNFα secretion, suspension THP-1 monocyte cells were
treated with DMSO (Thermo Fisher Scientific) at concentrations ranging from 0.016%2% for 5 min prior to subsequent treatment with 1 μg/mL Escherichia coli bacterial
026.B6 LPS (Sigma-Aldrich, St. Louis). Cells were incubated for 72 h at 37 °C in 5%
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CO2. DMSO concentrations were varied from 0.016%-2% to evaluate the effect on cell
response and specific concentrations for each experiment is detailed in each figure
legend. Control cell treatments without LPS but in the presence of DMSO were done
for all studies. For experiments assessing the regulatory role of cAMP on LPSstimulated MMP-9 and TNFα secretion, THP-1 monocytes were treated with cAMP
regulators dibutyryl 3',5'-cyclic adenosine monophosphate (Bt2-cAMP), forskolin (Fsk),
and 3-isobutyl-1-methylxanthine (IBMX) for 5 min prior to subsequent treatment with
1 μg/mL LPS. Cells were incubated for 6-72 h at 37 °C in 5% CO2. In one experiment,
cells were stimulated with 0.3 μg/mL LPS. Concentrations or concentration ranges
used for the regulators were 0.3 mmol/L for Bt2-cAMP, 0.01-0.1 mmol/L for Fsk, and
0.01-0.3 mmol/L for IBMX. Control cell treatments without LPS but in the presence of
cAMP regulators were done for all studies. For experiments assessing the effect of an
anti-human TNFα monoclonal antibody (MAB610, R&D Systems, Minneapolis, MN,
United States) on LPS-stimulated MMP-9 and TNFα secretion, THP-1 monocytes were
treated with the antibody for 5 min prior to subsequent treatment with 1 μg/mL LPS.
Cells were incubated for 48 h at 37 °C in 5% CO2. Control cell treatments with or
without LPS and/or in the presence or absence of the antibody, were done for these
studies. After all treatments, cells were removed from each well, centrifuged at 2500 g
for 10 min, and the supernatant was collected and frozen at −20 °C for subsequent
analysis.

Western blot
Supernatants from individual wells of treated THP-1 monocytes were mixed 1:1 with
Laemmli SDS sample buffer (Bio-Rad) containing 5% β-mercaptoethanol. Samples and
10 μL recombinant human MMP-9 western blotting standard (WBC018, R&D Systems,
Minneapolis, MN, United States) were heated at 95 °C for 5 min and separated on 7.5%
Tris-HCl gels (Ready Gel, Bio-Rad) under denaturing conditions (25 mmol/L Tris, 192
mmol/L glycine, 0.1% SDS at pH 8.3) using a Mini Protean 3 Cell (Bio-Rad). Prestained SDS-PAGE standards (BioRad) were loaded directly into gel wells. Gels were
transferred to Immobilon-P PVDF membrane (Millipore) in transfer buffer containing
25 mmol/L Tris base, 192 mmol/L glycine, and 10% methanol at pH 8.3 using a Tank
VEP-2 electroblotting system (Owl Separation Systems). Following protein transfer,
the membrane was blocked for 1 h at 25 °C with PBS containing 0.2% Tween 20 (PBST)
supplemented with 5% nonfat dry milk, and probed for 1 h at 25 °C with 1 μg/mL
goat anti-human MMP-9 antibody (AB911, R&D Systems) in PBST containing 1% milk.
After washing membrane 3× in PBST, the membrane was incubated with a 1:1000
dilution of goat anti-mouse IgG-HRP secondary antibody (R&D systems) in PBST
containing 1% milk for 1 h at 25 °C. Protein detection was accomplished using ECL
Western Blotting Substrate reagents (Pierce) and exposure to film (Kodak).
Densitometry of immunoblot TIFF images was done using ImageJ 1.52a.

Enzyme-linked immuno sorbent assay
Measurement of secreted TNFα in the supernatants was determined by enzyme-linked
immuno sorbent assay (ELISA). Briefly, 0.1 mL of 4 mg/mL monoclonal anti-human
TNFα capture antibody (MAB610, R&D Systems) was added to 96-well plates for
overnight incubation at room temperature. Wells were washed with PBS (HyClone)
containing 0.05% Tween-20 and blocked with 0.3 mL PBS containing 1% bull serum
albumin (BSA), 5% sucrose and 0.05% NaN3 for 1 h at room temperature. After
washing, successive additions of 0.05 mL samples or standards (2 h), 0.1 mL
biotinylated polyclonal anti-human TNFα detection antibody (BAF210, R&D Systems)
in 20 mmol/L Tris with 150 mmol/L NaCl and 0.1% BSA (2 h), 0.1 mL streptavidinHRP (R&D Systems) diluted 200 times with PBS containing 1% BSA (20 min), and 0.1
mL of equal volumes of 3,3',5,5'-tetramethylbenzidine and hydrogen peroxide (KPL,
Gaithersburg, MD, United States) (30 min). The reaction was stopped by the addition
of 1% H2SO4 solution. The optical density of each sample was analyzed at 450 nm with
a reference reading at 630 nm using a SpectraMax 340 absorbance platereader
(Molecular Devices, Union City, CA, United States). A standard curve was constructed
by sequential dilution of a TNFα standard from 2000-15 pg/mL. The concentration of
TNFα in the experimental samples was calculated from the standard curve

Preparation of Aβ
Amyloid-β peptide (Aβ42) (rPeptide, Bogarth, GA, United States) was dissolved in
100% hexafluoroisopropanol (Sigma) for 1 h, aliquotted into sterile microcentrifuge
tubes, dried in a vacuum centrifuge, and stored at -20 °C. Prior to cell treatment the
lyophilized peptides were resuspended in sterile water to 100 μmol/L peptide
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concentration and incubated at 4 °C for 24 h. Cells were exposed to a final
concentration of 17 μmol/L Aβ42 for selected times. For experiments conducted on
Aβ42-stimulated MMP-9 and TNFα secretion, THP-1 monocytes were treated with
Aβ42 at a final concentration of 17 μmol/L, and incubated for 6, 24, or 48 h at 37 °C in
5% CO2. Control cell treatments without Aβ42 were done with the same volume of
sterile water.

Statistical analysis
Two-tailed paired Student t-tests were performed for experiments when applicable to
determine the confidence limit at which two measurements were statistically different.
Analysis was applied to each data set and P values less than 0.05 were considered
significant and are designated in the Figures with a superscript a (a) for (P < 0.05) or
superscript b (b) for (P < 0.01).

RESULTS
In the course of investigating MMP-9 secretion by THP-1 human monocytes after
exposure to LPS, it was observed that DMSO had an inhibitory effect on this process.
Western blot analysis showed that MMP-9 secretion was sensitive to LPS
concentration, in that 1 μg/mL LPS triggered greater MMP-9 protein secretion
compared to 0.1 μg/mL LPS (Figure 1A). The inclusion of 2% DMSO almost
completely abolished the release of MMP-9 from THP-1 cells after stimulation with
LPS at either concentration (Figure 1A). Densitometry analysis of the immunoblot is
provided in Figure 1B. TNFα is a classical proinflammatory cytokine and LPS-induced
TNFα secretion in immune cells has been well-studied. Surprisingly, this process was
not inhibited by DMSO. The same samples in Figure 1A were analyzed for TNFα
levels by ELISA. As expected, 1 μg/mL LPS triggered greater TNFα secretion
compared to 0.1 μg/mL in THP-1 cells (Figure 1C). 2% DMSO did not diminish the
LPS-induced TNFα response indicating a MMP-9-selective effect by DMSO.
The observation that DMSO inhibited MMP-9 secretion in THP-1 monocytes
prompted additional investigation of concentration dependence. THP-1 cells were
exposed to increasing concentrations of DMSO prior to stimulation with 1 μg/mL LPS.
MMP-9 secretion, measured by immunoblot, was slightly diminished at 0.2% DMSO
and almost completely inhibited at 1% DMSO (Figure 2A). Densitometry analysis of
the Figure 2A immunoblot allowed non-linear curve fitting of the dose-dependent
DMSO effect on secreted MMP-9. The inhibition curve fit yielded an IC50 value of
0.64% DMSO (Figure 2B). Analysis of the same LPS/DMSO samples for TNFα levels
again showed no inhibitory effect of DMSO on LPS-stimulated TNFα secretion
(Figure 2C).
Addition of Bt2-cAMP, a cell-permeable cAMP analog that mimics the activity of
cAMP[12], to THP-1 monocytes prior to LPS treatment resulted in an inhibition of
MMP-9 secretion (40%), but only at the later cell-exposure time points (Figure 3A and
B). The effect of Bt2-cAMP on TNFα was very different in that TNFα secretion was
significantly inhibited (> 77%) at earlier and later time points. Fsk, an adenylyl cyclase
activator that can also raise intracellular cAMP levels[13], was tested for its ability to
alter LPS-induced MMP-9 and TNFα secretion. Due to the hydrophobic nature of Fsk,
DMSO was used as a vehicle in this 72 h LPS cell treatment experiment. The DMSO
concentration was carefully determined and controlled to fully ascertain the effect of
Fsk. DMSO did not inhibit LPS-induced MMP-9 secretion at 0.016% and 0.048%, but
0.16% DMSO did inhibit 50% of the control LPS monocyte treatment (Figure 4A and
B). Fsk potently inhibited MMP-9 secretion far in excess of any DMSO inhibition that
was observed at 30 μmol/L and 100 μmol/L, but not 10 μmol/L, Fsk (Figure 4A and
B). As in the earlier data, DMSO did not inhibit LPS-induced TNFα secretion
(Figure 4C). However, Fsk dose-dependently inhibited TNFα secretion, with 39%
inhibition at 10 μmol/L, 54% inhibition at 30 μmol/L, and 66% inhibition at 100
μmol/L (Figure 4C). The Fsk inhibition values were determined relative to the
corresponding DMSO-treated THP-1 monocytes. Fsk also inhibited LPS-induced TNFα
secretion at an early time point (6 h), with 57% and 47% inhibition observed at 30
μmol/L and 100 μmol/L respectively (data not shown).
In order to increase intracellular cAMP levels by a different pathway, the cellpermeable general cAMP phosphodiesterase (PDE) inhibitor IBMX was tested.
Treatment of THP-1 monocytes with a concentration range of IBMX prior to
application of LPS produced a dose-dependent inhibition of MMP-9 secretion
(Figure 5A). Quantitation of the immunoblot by densitometry yielded an inhibition
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Figure 1 Dimethyl sulfoxide inhibits lipopolysaccharide-induced matrix-metalloproteinase-9, but not tumor necrosis factor α, secretion.
THP-1 monocytes were treated in the absence or presence of dimethyl sulfoxide (2%) and with either sterile water or lipopolysaccharide (0.1 μg/mL or 1 μg/mL) for 72
h. A: Cells were collected, centrifuged at 500 g for 10 min and supernatant assessed for matrix-metalloproteinase-9 (MMP-9), SDS-PAGE/immunoblot of cell
supernatants. Lane 1 is an MMP-9 Western blotting standard (10 μL); B: Densitometry of Panel A. Each data bar is the average ± standard error for three
independent densitometry measurements; and C: TNFα levels were determined in cell supernatants by enzyme-linked immuno sorbent assay and each data bar is
the average ± std error for three independent measurements, Tumor necrosis factor α (TNFα). Statistical differences (aP < 0.05 or bP < 0.01) for 0.1 μg/mL or 1 μg/mL
lipopolysaccharide and dimethyl sulfoxide inhibition of MMP-9 or TNFα secretion are shown. DMSO: Dimethyl sulfoxide; LPS: Lipopolysaccharide; MMP-9: Matrixmetalloproteinase-9; TNFα: Tumor necrosis factor α.

plot that was then analyzed by nonlinear curve fitting. The fit produced an IC50 value
of 0.05 mmol/L for IBMX inhibition of MMP-9 secretion (Figure 5B, circles). The effect
of IBMX on TNFα secretion was also assessed in the same supernatant samples by
ELISA. A very similar dose-dependent inhibition was observed for TNFα as for MMP9 with an IC50 value of 0.08 mmol/L (Figure 5B, diamonds). The temporal and
connected relationship between LPS-induced secretion of TNFα and MMP-9 strongly
suggested that TNFα played a contributory role in MMP-9 secretion. This idea was
tested by the inclusion of an anti-TNFα antibody prior to LPS treatment of THP-1
monocytes. The presence of the TNFα antibody reduced the secretion of MMP-9 when
analyzed by immunoblot (Figure 6A). Quantitative analysis by densitometry showed
47% inhibition of MMP-9 by blocking TNFα (Figure 6B, left plot). As expected, the
presence of the TNFα antibody significantly reduced TNFα levels in the cell
supernatant (Figure 6B, right plot).
In an effort to examine MMP-9 and TNFα secretion by a cell-stimulator other than
LPS, the ability of Aβ42 oligomers to trigger THP-1 monocyte MMP-9 secretion was
examined. Hexafluoroisopropanol-treated and vacuum-dried Aβ42 was reconstituted
in sterile H2O and incubated for 24 h at 4 °C to allow oligomer formation. THP-1 cells
exposed to the Aβ42 oligomers began to secrete MMP-9 at 24 h of treatment, with a
much larger level by 48 h (Figure 7A). Comparison of the immunoblot densitometry
quantitation and ELISA measurement of secreted TNFα indicated that maximum
TNFα secretion occurred prior to MMP-9 secretion (Figure 7B). The temporal
relationship between to Aβ42 oligomer-induced TNFα secretion and MMP-9 secretion
was similar to that observed by LPS. Significant analysis was performed to rule out
any LPS contamination within the Aβ42 samples and delineate differences between
LPS and Aβ42 stimulation of monocytes. These analytical measures were described in
a previous publication[14]. The two pathogens, one exogenous (LPS) and one
endogenous (Aβ), both trigger pathways leading to MMP-9 secretion.
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Figure 2 Dimethyl sulfoxide inhibits lipopolysaccharide-induced matrix-metalloproteinase-9 in a dose-dependent fashion. A: SDSPAGE/immunoblot of cell supernatants; B: Densitometry of Panel A. Each data bar is the average ± standard error for three independent densitometry
measurements. Data were fit to a nonlinear inhibition equation, which produced an IC50 of 0.64%; and C: Tumor necrosis factor α levels were determined in cell
supernatants by enzyme-linked immuno sorbent assay and each data bar is the average ± standard error for three independent measurements. THP-1 monocytes
were treated with a concentration range of dimethyl sulfoxide (0.1%-1%) followed by lipopolysaccharide (1 μg/mL) for 72 h. Cells were collected, centrifuged at 500 g
for 10 min and supernatant assessed for (A) matrix-metalloproteinase-9 and (C) tumor necrosis factor α. DMSO: Dimethyl sulfoxide; MMP-9: Matrixmetalloproteinase-9; TNFα: Tumor necrosis factor α.

DISCUSSION
LPS triggers Toll-like receptor 4 (TLR4) activation and downstream signaling
pathways that include myeloid differentiation protein 88 and NF-kB-mediated
transcription and expression of innate immune genes such as TNFα and IL-1β[15-17]. LPS
also activates extracellular signal-regulated kinases 1/2, mitogen-activated kinase p38,
mitochondrial reactive oxygen species, and MMP-9 expression[6,18].
DMSO has long been recognized to have anti-inflammatory and analgesic
properties[19]. Although controversial, it has been used in a variety of formulations for
the treatment of interstitial cystitis, cutaneous scleroderma, and wound healing, with
an additional potential as an anti-viral[19]. Furthermore, as a polar, aprotic solvent
miscible with water, DMSO is widely used as a vehicle for hydrophobic compounds in
cellular assays. Here we show that application of low concentrations (0.2%-0.8%) of
DMSO to human monocytes inhibited the secretion of MMP-9. The mechanism by
which the inhibition occurred was not a generalized process as DMSO did not inhibit
secretion of TNFα, another inflammatory product and mediator. Cyclic AMP, on the
other hand, inhibited both TNFα and MMP-9 secretion. The manner in which cAMP
was generated in the monocytes did not influence the inhibitory outcome, whether by
direct application of a cell-permeable cAMP analog, cAMP synthesis by activation of
adenylyl cyclase, or boosting cAMP levels by inhibition of PDE.
Our findings indicated that DMSO concentration should be restricted to 0.4% or
below to avoid inadvertent inhibition of MMP-9 secretion. Furthermore, there are
specific distinctions in the mechanistic pathways by which MMP-9 and TNFα are
secreted, and the inhibitory effect of DMSO on MMP-9 secretion reveals one or more
areas of these mechanistic distinctions. Our DMSO inhibitory observations and
effective concentration were consistent with other studies. Majtan and Majtan[9]
previously demonstrated DMSO inhibition of MMP-9 transcription and synthesis in
TNFα-treated human keratinocytes[9]. We expanded our investigation by stimulating
monocytes further upstream with LPS and comparing both DMSO and cAMP
regulation of TNFα and MMP-9 secretion. The findings showed that DMSO did not
alter LPS-induced TNFα levels indicating a distinctive effect for MMP-9. Previous
studies have shown DMSO inhibition of MMP-2 in human aorta endothelial cells at
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Figure 3 Cyclic adenosine monophosphate inhibits lipopolysaccharide-induced matrix-metalloproteinase-9 and tumor necrosis factor α
secretion. A: SDS-PAGE/immunoblot of cell supernatants. Lane 1 is a matrix-metalloproteinase-9 (MMP-9) standard; B: Densitometry of Panel A. Each data bar is
the average ± standard error for three independent densitometry measurements; and C: Tumor necrosis factor α (TNFα) levels were determined in cell supernatants
by enzyme-linked immuno sorbent assay and each data bar is the average ± standard error for three independent measurements. THP-1 monocytes were treated
with 3',5'-cyclic adenosine monophosphate (300 μmol/L) followed by lipopolysaccharide (0.03 μg/mL) for 6, 48, and 72 h. Cells were collected, centrifuged at 500 g for
10 min and supernatant assessed for (A) MMP-9 and (C) TNFα. Statistical differences (aP < 0.05 or b P < 0.01) between MMP-9 secretion at different
lipopolysaccharide treatment times and 3',5'-cyclic adenosine monophosphate inhibition of either MMP-9 or TNFα secretion are shown. LPS: Lipopolysaccharide;
MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α; Bt2-cAMP: 3',5'-cyclic adenosine monophosphate.

slightly higher concentrations of 1%-3%[20]. For other inflammatory molecules, Elisia
et al[11] found that 0.5%-2% DMSO inhibited expression of numerous cytokines in
bacterial-stimulated whole blood samples and in the joints of arthritic mice[11]. The
findings on TNFα were mixed, with some inhibition observed at 2% DMSO in whole
blood, but no inhibition in the arthritic mouse paws. Hollebeeck et al[10] reported
DMSO inhibition of the intestinal Caco-2 cell inflammatory response in the range of
0.1%-0.5%. The cells were stimulated with IL-1β or a proinflammatory cocktail
consisting of IL-1β, TNFα, interferon-γ and LPS. Differential effects by DMSO were
observed, whereby DMSO inhibited transcription of IL-6, IL-1α, IL-1β, and
cyclooxygenase-2, but not IL-8 or TNFα.
Cyclic-AMP is a ubiquitous second messenger molecule that can modulate a
number of processes by direct binding to molecular targets or by activation of cAMPdependent protein kinase (PKA) and subsequent downstream phosphorylation.
Adenylyl cyclase and PDE tightly control cAMP levels by regulating synthesis and
degradation respectively. Cyclic AMP is well-recognized as an inflammation modifier
in a variety of cell types and an important therapeutic target (reviewed in[21,22]).
Attenuation of LPS-induced TNFα production by agents that raise cAMP levels was
specifically demonstrated in monocyte/macrophage cells[15,23]. Furthermore, elevation
of cAMP levels in neutrophils inhibited MMP-9 secretion and implicated cAMPdependent PKA in the process[7].
The mechanism by which cAMP regulates cytokine pathways has been widely
researched and there are multiple points at which this occurs. Two of these areas in
monocytes/macrophages include the orphan nuclear receptor Nr4a1 (Nur77) and the
nuclear factor κB transcriptional complex. Elevated cAMP levels induce Nur77
expression leading to repression of numerous inflammatory genes reviewed in[24].
Either incomplete or excessive phosphorylation of cAMP response element binding
protein can suppress TNFα transcription[25]. PKA can also regulate cAMP response
element binding protein/deoxyribonucleic acid binding in ganglioside and
plasminogen-induced microglial cytokine production[26]. It has been proposed for some
time that cAMP has a role as an inflammation gate-keeper[23]. Our results were
consistent with previous findings and showed that increased cAMP levels attenuated
LPS-induced MMP-9 and TNFα secretion.
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Figure 4 Activation of adenylyl cyclase inhibits lipopolysaccharide-induced matrix-metalloproteinase-9 and tumor necrosis factor α
secretion. A: SDS-PAGE/immunoblot of cell supernatants. Lane 9 is a matrix-metalloproteinase-9 standard; B: Densitometry of Panel A. Each data bar is the
average ± standard error for three independent densitometry measurements; and C: Tumor necrosis factor α (TNFα) levels were determined in cell supernatants by
enzyme-linked immuno sorbent assay and each data bar is the average ± standard error for three independent measurements. THP-1 monocytes were treated with
three forskolin (Fsk) concentrations that contained different percentages of dimethyl sulfoxide (DMSO), followed by lipopolysaccharide (1 μg/mL) for 72 h. Cells were
collected, centrifuged at 500 g for 10 min and supernatant assessed for matrix-metalloproteinase-9 and TNFα. The red dashed lines in Panels B and C represent
TNFα secretion induced by lipopolysaccharide (1 μg/mL) in the absence of DMSO or Fsk. Statistical differences (aP < 0.05 or bP < 0.01) between DMSO and DMSO +
Fsk are shown. LPS: Lipopolysaccharide; DMSO: Dimethyl sulfoxide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α; Fsk: Forskolin.

Several aspects of our data indicated that MMP-9 secretion was a distinct process
from TNFα secretion and occurred downstream. First, DMSO inhibited MMP-9, but
not TNFα, suggesting that the MMP-9 secretion process was selectively altered.
Second, cAMP inhibited both MMP-9 and TNFα with a similar potency, but at
different monocyte cell exposure time points. The pattern of cAMP inhibition for these
two molecules suggested that MMP-9 secretion lies downstream of TNFα and that
TNFα may a key component of the pathway leading to MMP-9 secretion. This
temporal relationship fit a model whereby early TNFα secretion directly led to later
MMP-9 secretion. Lastly, antibody-blocking of TNFα diminished MMP-9 secretion,
suggesting a direct link between TNFα secretion and MMP-9 secretion.
Bacterial LPS stimulation of human monocytic cells has been well-studied and
evokes a classical innate immune response to exogenous pathogens via TLR4. It is now
widely-recognized that endogenous pathogens, such as Aβ in Alzheimer’s disease, can
trigger similar pathways via TLR4 and other TLRs[14,27-29]. Stimulation of MMP-9
secretion by Aβ42 has been shown previously in THP-1 monocytes[30], murine
microglia[31], rat astrocytes[32], and human retinal pigment epithelial cells[33].
Furthermore, MMP-9 levels are significantly elevated in plasma from Alzheimer’s
disease patients[34] and in 5xFAD/MBP−/− transgenic mice[35]. Our findings show that
Aβ42 oligomer-induced MMP-9 secretion appears to follow the same temporal
pathway as LPS in that significant MMP-9 levels were not observed until later cell
exposure time points and well after TNFα release. The LPS and Aβ42 results fit a
mechanism whereby induced TNFα secretion and subsequent autocrine stimulation of
TNF receptor type 1 leads to MMP-9 production and secretion[36].

CONCLUSION
The cumulative data indicated that MMP-9 secretion was a distinct process from TNFα
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Figure 5 Inhibition of cyclic adenosine monophosphate phosphodiesterase inhibits lipopolysaccharide-induced matrixmetalloproteinase-9 and tumor necrosis factor α in a dose-dependent fashion. A: SDS-PAGE/WB of cell supernatants; and B: Densitometry of the
matrix-metalloproteinase-9 (MMP-9) immunoblot in Panel A (circles). Each data point is the average ± standard error for three independent densitometry
measurements. Tumor necrosis factor α (TNFα) levels (diamonds) were determined in cell supernatants by enzyme-linked immuno sorbent assay and each data
point is the average ± standard error for three independent measurements. THP-1 monocytes were treated with a concentration range of 3-isobutyl-1-methylxanthine
(0.01-0.3 mmol/L) followed by lipopolysaccharide (1 μg/mL) for 48 h. Cells were collected, centrifuged at 500 g for 10 min and supernatant assessed for (A) MMP-9
and (B) TNFα. MMP-9 and TNFα data points were fit to a nonlinear inhibition equation, which produced IC50 values of 0.05 mmol/L and 0.08 mmol/L for MMP-9 and
TNFα inhibition respectively. LPS: Lipopolysaccharide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α; IBMX: 3-Isobutyl-1-methylxanthine.

secretion and occurred downstream. First, DMSO inhibited MMP-9, but not TNFα,
suggesting that the MMP-9 secretion process was selectively altered. Second, cAMP
inhibited both MMP-9 and TNFα with a similar potency, but at different monocyte cell
exposure time points. The pattern of cAMP inhibition for these two molecules
suggested that MMP-9 secretion lies downstream of TNFα and that TNFα may a key
component of the pathway leading to MMP-9 secretion. This temporal relationship fit
a model whereby early TNFα secretion directly led to later MMP-9 secretion. Lastly,
antibody-blocking of TNFα diminished MMP-9 secretion, suggesting a direct link
between TNFα secretion and MMP-9 secretion.
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Figure 6 Antif- tumor necrosis factor α antibody blocks lipopolysaccharide-induced matrix-metalloproteinase-9 secretion. THP-1 monocytes
were treated with a tumor necrosis factor α (TNFα) antibody (1 μg/mL) followed by lipopolysaccharide (1 μg/mL) for 48 h. Cells were collected, centrifuged at 500 g for
10 min and supernatant assessed for matrix-metalloproteinase-9 and TNFα. A: SDS-PAGE/WB of cell supernatants; and B: Densitometry of Panel A (left plot). Each
data bar is the average ± standard error for three independent densitometry measurements. TNFα levels (right plot) were determined in cell supernatants by enzymelinked immuno sorbent assay and each data bar is the average ± standard error for three independent measurements. Statistical differences (aP < 0.05 or bP < 0.01)
between lipopolysaccharide-stimulated matrix-metalloproteinase-9 or TNFα secretion compared to PBS buffer control and in the absence or presence of an antiTNFα antibody are shown. LPS: Lipopolysaccharide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α.

Figure 7 Amyloid-β peptide-induced matrix-metalloproteinase-9 secretion occurs much later than tumor necrosis factor α secretion. THP1 monocytes were treated with amyloid-β peptide (17 μmol/L) for 6, 24 and 48 h. Cells were collected, centrifuged at 500 g for 10 min and supernatant assessed for
matrix-metalloproteinase-9 (MMP-9) and tumor necrosis factor α (TNFα). A: SDS-PAGE/WB of cell supernatants. Lane 1 is an MMP-9 standard; and B: Densitometry
of Panel A (left plot). Each data bar is the average ± standard error for three independent densitometry measurements. Enzyme-linked immuno sorbent assay
determination of TNFα levels in cell supernatants (right plot). Each data bar is the average ± standard error for three independent measurements. Statistical
differences (aP < 0.05 or bP < 0.01) between MMP-9 or TNFα secretion at different amyloid-β peptide treatment times are shown with an asterisk. Aβ42: Amyloid-β
peptide; MMP-9: Matrix-metalloproteinase-9; TNFα: Tumor necrosis factor α.
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ARTICLE HIGHLIGHTS
Research background
Matrix metalloproteinases (MMPs), including MMP-9, are an integral part of the
immune response and are upregulated in response to a variety of stimuli. New details
continue to emerge concerning the mechanistic and regulatory pathways that mediate
MMP-9 secretion. There is significant evidence for regulation of inflammation by
dimethyl sulfoxide (DMSO) and 3',5'-cyclic adenosine monophosphate (cAMP), thus
investigation of how these two molecules may regulate both MMP-9 and tumor
necrosis factor α (TNFα) secretion by human monocytes was of high interest. The
hypothesis tested in this study was that DMSO and cAMP regulate MMP-9 and TNFα
secretion by distinct mechanisms.

Research motivation
The objective of this study was further examine temporal and regulatory mechanisms
of MMP-9 secretion in THP-1 human monocytes after stimulation with
lipopolysaccharide (LPS). Specifically, dose-dependent regulation of MMP-9 and
TNFα by the aprotic solvent DMSO and the intracellular signaling molecule cAMP.

Research objectives
The objective of this study was further examine temporal and regulatory mechanisms
of MMP-9 secretion in THP-1 human monocytes after stimulation with LPS.
Specifically, dose-dependent regulation of MMP-9 and TNFα by the aprotic solvent
DMSO and the intracellular signaling molecule cAMP.

Research methods
The paper describes a basic research study using THP-1 human monocyte cells. All
experiments were conducted at the University of Missouri-St. Louis in the Department
of Chemistry and Biochemistry. Human monocyte cells were grown, cultured, and
prepared for experiments in the University of Missouri-St. Louis Cell Culture Facility
as per accepted guidelines. Cells were treated with LPS for selected exposure times
and the conditioned medium was collected for analysis of MMP-9 and TNFα
production. Inhibitors including DMSO, cAMP regulators, and anti-TNFα antibody
were added to the cells prior to LPS treatment. MMP-9 secretion was analyzed by gel
electrophoresis/western blot and quantitated by ImageJ software. TNFα secretion was
analyzed by enzyme-linked immuno sorbent assay. All data is presented as the
average and standard error for at least 3 trials. Statistical analysis was done using a
two-tailed paired Student t-test P values less than 0.05 were considered significant and
designated as such with an asterisk in the figures (P < 0.05). LPS and cAMP regulators
were from Sigma-Aldrich, MMP-9 standard and antibody and TNFα antibodies were
from R&D Systems, and amyloid-β peptide was from rPeptide.

Research results
In our investigation of MMP-9 secretion from THP-1 human monocytes, we made the
following findings. Inclusion of DMSO in the cell treatment inhibited LPS-induced
MMP-9, but not TNFα, secretion. Inclusion of DMSO in the cell treatment at different
concentrations inhibited LPS-induced MMP-9 secretion in a dose-dependent fashion.
A cell-permeable cAMP analog, dibutyryl cAMP, inhibited both LPS-induced MMP-9
and TNFα secretion. Pretreatment of the cells with the adenylyl cyclase activator
forskolin inhibited LPS-induced MMP-9 and TNFα secretion. Pretreatment of the cells
with the general cAMP phosphodiesterase inhibitor reduced LPS-induced MMP-9 and
TNFα in a dose-dependent fashion. Pre-treatment of monocytes with an anti-TNFα
antibody blocked LPS-induced MMP-9 and TNFα secretion. Amyloid-β peptideinduced MMP-9 secretion and occurred much later than TNFα secretion. The latter
two findings strongly suggested an upstream role for TNFα in mediating LPSstimulate MMP-9 secretion.

Research conclusions
The cumulative data indicated that MMP-9 secretion was a distinct process from TNFα
secretion and occurred downstream. First, DMSO inhibited MMP-9, but not TNFα,
suggesting that the MMP-9 secretion process was selectively altered. Second, cAMP
inhibited both MMP-9 and TNFα with a similar potency, but at different monocyte cell
exposure time points. The pattern of cAMP inhibition for these two molecules
suggested that MMP-9 secretion lies downstream of TNFα and that TNFα may a key
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component of the pathway leading to MMP-9 secretion. This temporal relationship fit
a model whereby early TNFα secretion directly led to later MMP-9 secretion. Lastly,
antibody-blocking of TNFα diminished MMP-9 secretion, suggesting a direct link
between TNFα secretion and MMP-9 secretion.

Research perspectives
Regulation of MMP-9 is a significant important in many disease processes including
arthritis and Alzheimer’s disease. Further understanding of the pathways leading to
MMP-9 secretion and regulation of this process will be important for managing human
health.
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